Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short
Portfolio Pulse from
Eli Lilly has lowered its full-year revenue forecast due to slower-than-expected sales growth of its weight-loss drugs, Mounjaro and Zepbound. The company's shares fell 7.3% following the announcement.
January 14, 2025 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's shares fell 7.3% after the company lowered its full-year revenue forecast due to slower-than-expected sales growth of its weight-loss drugs, Mounjaro and Zepbound.
The announcement of slower sales growth for key products Mounjaro and Zepbound led to a significant drop in Eli Lilly's stock price. The company's revised revenue forecast indicates potential challenges in meeting market expectations, impacting investor sentiment negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100